核苷(酸)类似物抗病毒治疗慢性重型乙型肝炎的疗效观察

摘要

目的 观察核苷(酸)类似物的抗病毒治疗慢性重型乙型肝炎的临床疗效.方法 将我院2010年1月至2012年1月之间收录的88例慢性重型乙型肝炎患者随机的分为两组，对照组的44例患者采取常规方法进行治疗，而观察组的44例患者在常规的基础上采取核苷(酸)类似物的抗病毒进行治疗，观察两组治疗后的情况.结果 两组的治疗结果对比，两组的患者在治疗3月后的 PTA 和 TBil 以及 ALT与 HBV-DNA 等的改善情况明显的优于治疗前的水平，比较具有明显的差异(P <0.05)，统计学有意义；观察组治疗3个月后的 PTA 明显的高于对照组的 PTA 情况，比较具有明显的差异(P <0.05)，统计学有意义.观察组在治疗3个月后的存活率明显的高于对照组的情况，比较具有明显的差异(P <0.05)，统计学有意义.结论 对于慢性重型乙型肝炎患者采取核苷(酸)类似物的抗病毒治疗能够降低患者的病死率，有效地改善患者的肝功能，值得临床中应用.%　　Objective To observe the nucleoside analogue antiviral treatment of chronic severe hepatitis B clinical efficacy (acid). Methods  Our hospital between January 2010 to January 2012, included 88 patients with chronic severe hepatitis B patients were randomly divided into two groups, the control group of 44 patients taking conventional methods for treatment, and 44 of the observation group patients nucleoside (acid) analogues antiviral treatment, observed after treatment were taken on a regular basis. Results  The two groups of treatment results compared two groups of patients in the PTA and TBil after 3 months of treatment, and ALT and HBV-DNA, etc. to improve the situation significantly better than the pre-treatment level, compared with a significant difference (P <0.05 ), statistically meaningful; observation group therapy three months after PTA significantly higher than PTA compared with obvious differences (P <0.05), statistically meaningful. Observation group after 3 months of treatment, the survival rate was significantly higher than that in the control group compared with significant differences (P <0.05), statistically meaningful. Nucleoside (acid) analogues of antiviral therapy Conclusion For patients with chronic severe hepatitis B take to reduce the mortality rate of the patients, to improve the patient's liver function, worthy of clinical application.